Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Alterations of genes encoding Sirt1, Mfn1 and Drp1 in an experimental model of AD suggest that modulation of mitochondria dynamics and Sirt1, including miRNA strategy, may be crucial for improvement of AD therapy.
|
31734880 |
2020 |
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
There are several PPIs which are current topics of research including Drp1, Aβ interactions with various targets including PrPC, Fyn kinase, NMDAR and mGluR5 and interaction of Mint2 with PDZ domain, etc., and thus have potential role in neurodegeneration and AD.
|
30836921 |
2019 |
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
A similar ApoE4-driven decrease in DRP-1 was also observed in AD brains.
|
31306119 |
2019 |
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
This suggests that Drp1/Fis1 interaction and excessive mitochondrial fission greatly contribute to Aβ-mediated and AD-related neuropathology and cognitive decline.
|
29464060 |
2018 |
Alzheimer's Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Drp1 activity and mitochondria fragmentation are significantly elevated in the brains of sporadic Alzheimer's disease (AD) cases.
|
28432138 |
2017 |
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Aqua-soluble DDQ reduces the levels of Drp1 and Aβ and inhibits abnormal interactions between Aβ and Drp1 and protects Alzheimer's disease neurons from Aβ- and Drp1-induced mitochondrial and synaptic toxicities.
|
28854701 |
2017 |
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
The protective effect of Drp1 on the Aβ42 transgenic Drosophila was achieved by protecting the mitochondrial function, suggesting that Drp1 may be a potential therapeutic strategies for AD.
|
28531191 |
2017 |
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Based on these findings, we hypothesize that a partial deficiency of Drp1 inhibits Drp1-Aβ interactions and protects Aβ-induced mitochondrial and synaptic toxicities, and maintains mitochondrial dynamics and neuronal function in AD neurons.
|
27677309 |
2016 |
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our findings indicate that aberrant S-nitrosylation of Drp1 is a prominent pathological feature of neurodegenerative diseases such as AD and HD.
|
23641925 |
2013 |
Alzheimer's Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
S-Nitrosylation of DRP1 does not affect enzymatic activity and is not specific to Alzheimer's disease.
|
20463395 |
2010 |
Alzheimer's Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Immunoblot analysis revealed that levels of DLP1 (also referred to as Drp1), OPA1, Mfn1, and Mfn2 were significantly reduced whereas levels of Fis1 were significantly increased in AD.
|
19605646 |
2009 |
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
We found that nitric oxide produced in response to beta-amyloid protein, thought to be a key mediator of Alzheimer's disease, triggered mitochondrial fission, synaptic loss, and neuronal damage, in part via S-nitrosylation of dynamin-related protein 1 (forming SNO-Drp1).
|
19342591 |
2009 |